Trials / Completed
CompletedNCT01121562
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
A Phase II Study Of Sunitinib In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib | Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days) |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2011-07-01
- Completion
- 2013-11-01
- First posted
- 2010-05-12
- Last updated
- 2014-06-30
- Results posted
- 2012-08-27
Locations
4 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01121562. Inclusion in this directory is not an endorsement.